Liver cancer incidence is growing faster than any other cancer in men and women. It is evident that the optimal care of patients with HCC necessitates the involvement of a multidisciplinary team utilizing evidence-based cancer guidelines.

Over the last three years, results have been reported on large and/or national/international clinical trials in pediatric CNS tumors and radiotherapy.

It is imperative that radiation oncologists remain current in state of the art clinical trials, and moreover that they understand how to utilize this data to provide appropriate patient care.

This activity will discuss current clinical scenarios in prostate cancer with an expert panel discussing decision points starting from a patient case but expanding to include audience responses, the panel's opinion, and finally discussing the evidence and guidelines for each situation.

This course will discuss current evidence and emerging treatment options in the management of SCLC. An overview of small cell lung cancer (SCLC) will be provided including definitions, staging, epidemiology, pathology and ongoing clinical trials.

In this course, through complex head and neck case examples, a multidisciplinary panel will discuss the relative merits of primary chemoradiation approaches and/or surgical approaches for locally advanced head and neck cancer in the context of optimizing cure, while considering organ preservation

Biomarkers have revolutionized how we treat certain cancers (e.g. breast cancer, medulloblastoma, H&N cancer, etc.), sometimes even providing more prognostic information than traditional measures such as age, stage, grade and performance status.

At the PRO session for the AM2018, it was noted that community radiation oncologists are increasingly finding oligometastases as part of their practice or being referred these patients after advanced staging by medical oncology or urology.

This course is designed to reinforce and expand knowledge, techniques and updates in gynecological radiation oncology.

This activity is available from March 30, 2020, through 11:59 p.m. Eastern time on March 29, 2023.

This course will review the new data and standard of care for each disease state of prostate cancer.  It will start with very low risk disease and go through intermediate risk, high risk, locally advanced, node positive, oligometastatic, and post-operative and will describe what the presenter wou